$0.80
6.60% today
NYSE, Apr 03, 06:46 pm CET
ISIN
US1420381089
Symbol
CRBU
Sector
Industry

Caribou Biosciences Target price 2025 - Analyst rating & recommendation

Caribou Biosciences Classifications & Recommendation:

Buy
88%
Hold
13%

Caribou Biosciences Price Target

Target Price $12.00
Price $0.86
Potential
Number of Estimates 7
7 Analysts have issued a price target Caribou Biosciences 2026 . The average Caribou Biosciences target price is $12.00. This is higher than the current stock price. The highest price target is
$34.00 3,848.90%
register free of charge
, the lowest is .
A rating was issued by 8 analysts: 7 Analysts recommend Caribou Biosciences to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Caribou Biosciences stock has an average upside potential 2026 of . Most analysts recommend the Caribou Biosciences stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 9.99 9.13
71.03% 8.56%
EBITDA Margin -1,628.53% -1,952.76%
398.99% 19.91%
Net Margin -1,525.80% -1,122.59%
312.67% 26.43%

7 Analysts have issued a sales forecast Caribou Biosciences 2025 . The average Caribou Biosciences sales estimate is

$9.1m
Unlock
. This is
8.56% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$14.0m 40.14%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $10.0m 71.03%
2025
$9.1m 8.56%
Unlock
2026
$25.5m 179.06%
Unlock
2027
$43.6m 71.05%
Unlock
2028
$277m 534.99%
Unlock
2029
$1.8b 558.43%
Unlock

2 Analysts have issued an Caribou Biosciences EBITDA forecast 2025. The average Caribou Biosciences EBITDA estimate is

$-178m
Unlock
. This is
9.64% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-169m 3.64%
Unlock
, the lowest is
$-188m 15.64%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-163m 44.57%
2025
$-178m 9.64%
Unlock
2026
$-190m 6.57%
Unlock
2027
$4.8m 102.54%
Unlock

EBITDA Margin

2024 -1,628.53% 398.99%
2025
-1,952.76% 19.91%
Unlock
2026
-745.78% 61.81%
Unlock
2027
11.08% 101.49%
Unlock

2 Caribou Biosciences Analysts have issued a net profit forecast 2025. The average Caribou Biosciences net profit estimate is

$-103m
Unlock
. This is
32.73% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-75.8m 50.30%
Unlock
, the lowest is
$-129m 15.15%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-152m 19.57%
2025
$-103m 32.73%
Unlock
2026
$-84.1m 18.01%
Unlock
2027
$-32.3m 61.54%
Unlock
2028
$-32.3m 0.00%
Unlock
2029
$920k 102.85%
Unlock

Net Margin

2024 -1,525.80% 312.67%
2025
-1,122.59% 26.43%
Unlock
2026
-329.80% 70.62%
Unlock
2027
-74.16% 77.51%
Unlock
2028
-11.68% 84.25%
Unlock
2029
0.05% 100.43%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share $ -1.65 -1.11
19.57% 32.73%
P/E negative
EV/Sales negative

2 Analysts have issued a Caribou Biosciences forecast for earnings per share. The average Caribou Biosciences EPS is

$-1.11
Unlock
. This is
32.73% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.82 50.30%
Unlock
, the lowest is
$-1.40 15.15%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.65 19.57%
2025
$-1.11 32.73%
Unlock
2026
$-0.91 18.02%
Unlock
2027
$-0.35 61.54%
Unlock
2028
$-0.35 0.00%
Unlock
2029
$0.01 102.86%
Unlock

P/E ratio

Current -0.52 85.35%
2025
-0.78 50.00%
Unlock
2026
-0.95 21.79%
Unlock
2027
-2.46 158.95%
Unlock
2028
-2.46 0.00%
Unlock
2029
86.10 3,600.00%
Unlock

Based on analysts' sales estimates for 2025, the Caribou Biosciences stock is valued at an EV/Sales of

-11.27
Unlock
and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -10.31 318.43%
2025
-11.27 9.32%
Unlock
2026
-4.04 64.16%
Unlock
2027
-2.36 41.54%
Unlock
2028
-0.37 84.25%
Unlock
2029
-0.06 84.81%
Unlock

P/S ratio

Current 8.02 40.46%
2025
8.77 9.37%
Unlock
2026
3.14 64.16%
Unlock
2027
1.84 41.54%
Unlock
2028
0.29 84.25%
Unlock
2029
0.04 84.82%
Unlock

Current Caribou Biosciences Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Mar 19 2025
B of A Securities
Locked
Locked
Locked Jan 07 2025
Citigroup
Locked
Locked
Locked Nov 26 2024
HC Wainwright & Co.
Locked
Locked
Locked Nov 15 2024
HC Wainwright & Co.
Locked
Locked
Locked Sep 03 2024
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 19 2025
Locked
B of A Securities:
Locked
Locked
Jan 07 2025
Locked
Citigroup:
Locked
Locked
Nov 26 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Nov 15 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Sep 03 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today